RIOK1 and cancer: Interestingly, while previous studies have linked the sensitivity of cancer cell lines to PRMT5 inhibition to MTAP status30, TP53 mutations28, or CLNS1A/RIOK1 ratio34, none of these factors correlated with response in our patient-derived samples.